Tiffany Olson
Tiffany Olson's purchase track record
Tiffany Olson has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/29/2022 | CSTL | $25K | +15.1% | +12.6% | +6.3% |
| 5/12/2022 | CSTL | $25K | +80.3% | +10.8% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Castle Biosciences to Release Q3 2026 Results and New Barrett's Data. Castle Biosciences announced it will release its third‑quarter 2026 financial results on Thursday, November 5, and will host a webcast. The company also plans to present new data from three studies on its TissueCypher Barrett’s Esophagus test at the ACG 2026 annual scientific meeting, showing the test can identify elevated risk of progression beyond pathology findings. These updates give the market fresh information on both the company's earnings and the clinical relevance of its main product.
Transaction History
| MDXG | ▲ Buy | Grant | 50,913 | $185K | 6/10/2026 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 13,667 | — | 5/22/2026 | View on chart |
| MDXG | ▲ Buy | Grant | 28,609 | $185K | 6/18/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 8,673 | — | 5/21/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 830 | — | 7/1/2024 | View on chart |
| MDXG | ▲ Buy | Grant | 28,988 | $210K | 6/5/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 8,636 | — | 5/25/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 487 | — | 5/10/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 3,825 | — | 6/2/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 487 | — | 5/10/2023 | View on chart |
| CSTL | ▲ Buy | Open Market | 1,162 | $25K | 11/29/2022 | View on chart |
| CSTL | ▲ Buy | Open Market | 220 | $4K | 5/12/2022 | View on chart |
| CSTL | ▲ Buy | Open Market | 1,100 | $21K | 5/12/2022 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 486 | — | 5/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification
A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.
MiMedx Wins Favorable Court Ruling on AXIOFILL Classification. A U.S. federal court ruled that MiMedx’s product AXIOFILL is not subject to the FDA’s regulatory classification that had limited its use. The decision removes a major regulatory hurdle for the company’s regenerative medicine line. The ruling could improve market perception and support future sales. The stock is currently near its 12‑month support level.